DNLI
Price
$12.52
Change
-$0.34 (-2.64%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
1.87B
33 days until earnings call
HALO
Price
$57.72
Change
-$2.93 (-4.83%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
7.13B
33 days until earnings call
Ad is loading...

DNLI vs HALO

Header iconDNLI vs HALO Comparison
Open Charts DNLI vs HALOBanner chart's image
Denali Therapeutics
Price$12.52
Change-$0.34 (-2.64%)
Volume$32.73K
Capitalization1.87B
Halozyme Therapeutics
Price$57.72
Change-$2.93 (-4.83%)
Volume$49.73K
Capitalization7.13B
DNLI vs HALO Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. HALO commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and HALO is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (DNLI: $12.86 vs. HALO: $60.65)
Brand notoriety: DNLI and HALO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 163% vs. HALO: 144%
Market capitalization -- DNLI: $1.82B vs. HALO: $7.13B
DNLI [@Biotechnology] is valued at $1.82B. HALO’s [@Biotechnology] market capitalization is $7.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $263.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileHALO’s FA Score has 2 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • HALO’s FA Score: 2 green, 3 red.
According to our system of comparison, HALO is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while HALO’s TA Score has 6 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 3 bearish.
  • HALO’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, HALO is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -6.40% price change this week, while HALO (@Biotechnology) price change was -3.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.53%. For the same industry, the average monthly price growth was -18.05%, and the average quarterly price growth was -19.90%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

HALO is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (-7.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($7.13B) has a higher market cap than DNLI($1.87B). HALO YTD gains are higher at: 26.856 vs. DNLI (-36.899). HALO has higher annual earnings (EBITDA): 657M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. HALO (596M). DNLI has less debt than HALO: DNLI (48.7M) vs HALO (1.51B). HALO has higher revenues than DNLI: HALO (1.02B) vs DNLI (0).
DNLIHALODNLI / HALO
Capitalization1.87B7.13B26%
EBITDA-492.89M657M-75%
Gain YTD-36.89926.856-137%
P/E RatioN/A16.82-
Revenue01.02B-
Total Cash832M596M140%
Total Debt48.7M1.51B3%
FUNDAMENTALS RATINGS
DNLI vs HALO: Fundamental Ratings
DNLI
HALO
OUTLOOK RATING
1..100
6669
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
10022
SMR RATING
1..100
3811
PRICE GROWTH RATING
1..100
9343
P/E GROWTH RATING
1..100
9857
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HALO's Valuation (81) in the Biotechnology industry is in the same range as DNLI (94). This means that HALO’s stock grew similarly to DNLI’s over the last 12 months.

HALO's Profit vs Risk Rating (22) in the Biotechnology industry is significantly better than the same rating for DNLI (100). This means that HALO’s stock grew significantly faster than DNLI’s over the last 12 months.

HALO's SMR Rating (11) in the Biotechnology industry is in the same range as DNLI (38). This means that HALO’s stock grew similarly to DNLI’s over the last 12 months.

HALO's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for DNLI (93). This means that HALO’s stock grew somewhat faster than DNLI’s over the last 12 months.

HALO's P/E Growth Rating (57) in the Biotechnology industry is somewhat better than the same rating for DNLI (98). This means that HALO’s stock grew somewhat faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIHALO
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
63%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
65%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 14 days ago
79%
Bullish Trend 21 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
67%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VCR322.8932.47
+11.18%
Vanguard Consumer Discretionary ETF
EWS22.242.02
+9.99%
iShares MSCI Singapore ETF
RNEM51.474.10
+8.66%
First Trust Emerging Markets Eq Sel ETF
SSPY74.805.43
+7.84%
Stratified LargeCap Index ETF
EVM8.84-0.21
-2.32%
Eaton Vance California Municipal

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RCKT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+12.12%
RCKT - DNLI
60%
Loosely correlated
+12.53%
BEAM - DNLI
58%
Loosely correlated
+12.59%
NTLA - DNLI
56%
Loosely correlated
+12.74%
ARWR - DNLI
56%
Loosely correlated
+18.12%
CRSP - DNLI
54%
Loosely correlated
+11.58%
More